These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38423193)
1. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease. Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193 [TBL] [Abstract][Full Text] [Related]
2. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients. Krauss S; Nalavade R; Weber S; Carter K; Evert BO Microrna; 2019; 8(1):76-85. PubMed ID: 30147021 [TBL] [Abstract][Full Text] [Related]
8. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3. Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201 [TBL] [Abstract][Full Text] [Related]
9. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse. Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651 [TBL] [Abstract][Full Text] [Related]
10. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3. Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633 [TBL] [Abstract][Full Text] [Related]
11. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700 [TBL] [Abstract][Full Text] [Related]
12. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
13. Transcript diversity of Machado-Joseph disease gene (ATXN3) is not directly determined by SNPs in exonic or flanking intronic regions. Bettencourt C; Raposo M; Ros R; Montiel R; Bruges-Armas J; Lima M J Mol Neurosci; 2013 Mar; 49(3):539-43. PubMed ID: 22706685 [TBL] [Abstract][Full Text] [Related]
14. Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the Lian M; Tan VJ; Taguchi R; Zhao M; Phang GP; Tan AS; Liu S; Lee CG; Chong SS Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125643 [TBL] [Abstract][Full Text] [Related]
15. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002 [TBL] [Abstract][Full Text] [Related]
16. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics. Paulino R; Nóbrega C Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570 [TBL] [Abstract][Full Text] [Related]
17. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Chen ZS; Huang X; Talbot K; Chan HYE Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212 [TBL] [Abstract][Full Text] [Related]
18. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]